177 related articles for article (PubMed ID: 35999259)
1. Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.
Yen R; Grasedieck S; Wu A; Lin H; Su J; Rothe K; Nakamoto H; Forrest DL; Eaves CJ; Jiang X
Leukemia; 2022 Oct; 36(10):2443-2452. PubMed ID: 35999259
[TBL] [Abstract][Full Text] [Related]
2. Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
Wu A; Yen R; Grasedieck S; Lin H; Nakamoto H; Forrest DL; Eaves CJ; Jiang X
Leukemia; 2023 Dec; 37(12):2426-2435. PubMed ID: 37848633
[TBL] [Abstract][Full Text] [Related]
3. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Wang R; Cong Y; Li C; Zhang C; Lin H
Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
[TBL] [Abstract][Full Text] [Related]
6. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
7. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
8. Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.
Mohd Yacob A; Muhamad NA; Chang KM; Akmal Hisham H; Mat Yusoff Y; Ibrahim L
BMC Cancer; 2022 Mar; 22(1):332. PubMed ID: 35346116
[TBL] [Abstract][Full Text] [Related]
9. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
10. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
11. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
12. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
14. miRNAs in chronic myeloid leukemia: small molecules, essential function.
Litwińska Z; Machaliński B
Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
[TBL] [Abstract][Full Text] [Related]
15. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p.
Sukegawa M; Wang X; Nishioka C; Pan B; Xu K; Ohkawara H; Hamasaki Y; Mita M; Nakamura K; Okamoto M; Shimura H; Ohta M; Ikezoe T
Leuk Res; 2017 Jul; 58():83-90. PubMed ID: 28501737
[TBL] [Abstract][Full Text] [Related]
16. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
17. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Nishioka C; Ikezoe T; Yang J; Nobumoto A; Tsuda M; Yokoyama A
Cancer Sci; 2014 Mar; 105(3):297-307. PubMed ID: 24350829
[TBL] [Abstract][Full Text] [Related]
20. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
